Rocket


Overview
Financials
News + Filings





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Appointed director
CC transcript

Synaptogenix, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
04/13/2021 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
04/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan"
03/12/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/01/2021 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/17/2021 8-K Quarterly results
02/12/2021 D Form D - Notice of Exempt Offering of Securities:
02/11/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2021 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
01/22/2021 8-K Quarterly results
01/19/2021 8-K Quarterly results
12/23/2020 10-Q Quarterly Report for the period ended September 30, 2020
12/16/2020 8-K Conference call transcript
Docs: "Script of Synaptogenix, Inc. conference call held on December 15, 2020"
12/10/2020 8-K Appointed a new director
Docs: "Amended and Restated Articles of Incorporation of Synaptogenix, Inc.",
"Bylaws of Synaptogenix, Inc",
"Separation and Distribution Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"Tax Matters Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"SEPARATION AGREEMENT",
"Dr. Alan J. Tuchman",
"SYNAPTOGENIX, INC. 2020 EQUITY INCENTIVE PLAN 1. DEFINITIONS.",
"STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS",
"Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's disease and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual ..."
11/20/2020 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/12/2020 424B1 Form 424B1 - Prospectus [Rule 424(b)(1)]:
11/10/2020 EFFECT Form EFFECT - Notice of Effectiveness:
11/05/2020 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
10/09/2020 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
09/05/2013 D Form D - Notice of Exempt Offering of Securities
03/13/2013 D Form D - Notice of Exempt Offering of Securities

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy